Kimberly L. Schultz
FDA investigator
Appears on 1 document from 2019, mostly at sites in New Jersey. Most often cites sampling and testing of in-process materials and drug products (21 CFR 211.110(a)).
- 1
- Documents on file
- 4.0
- Observations per 483
- 2019
- First seen
- 2019
- Most recent
What they cite most
From 4 observations- 21 CFR 211.110(a)Sampling and testing of in-process materials and drug products1
- 21 CFR 211.113(b)Control of microbiological contamination1
- 21 CFR 211.180(e)(2)General requirements1
- 21 CFR 211.192Production record review1
Activity by year
2019: 1
Where
New Jersey 1
Often inspects with
Is Kimberly L. Schultz coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2019-08-21 | 483 Novartis Pharmaceuticals CorporationAug 21, 2019 · Morris Plains, New Jersey | Morris Plains, New Jersey | 4 |
About this profile
What does Kimberly L. Schultz inspect?
Kimberly L. Schultz appears on 1 document on file covering 1 site, mostly in New Jersey.
What do they cite most often?
21 CFR 211.110(a) (sampling and testing of in-process materials and drug products), followed by 21 CFR 211.113(b) and 21 CFR 211.180(e)(2).
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Kimberly L. Schultz is dated Aug 21, 2019.